Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J.; Reckamp, K.; Baas, P.; Crinò, L.; Eberhardt, W.; Poddubskaya, E.; Antonia, S.; Płużański, A.; Vokes, E.; Holgado, E.; Waterhouse, D.; Ready, N.; Gainor, J.; A. Frontera, O.; Havel, L.; Steins, M.; Garassino, M.; Aerts, J.; Dómine, M.; Paz-Ares, L.; Reck, M.; Baudelet, C.; Harbison, C.; Lestini, B.; Spigel, D.

doi:10.1056/NEJMoa1504627

Public

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Shared by NobleBlocks on May 31, 2015 • 12:00 AM UTC

Authors:

J. Brahmer

K. Reckamp

P. Baas

Abstract

Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully hu...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!